The H1N1 (swine flu) Vaccination Market was valued at USD 3.54 billion in 2023 and is expected to reach USD 6.14 billion by 2032, growing at a CAGR of 6.32% from 2024 to 2032.
Our H1N1 (Swine Flu) Vaccination Market report offers in-depth insights outside the scope of generic market growth. We have presented comprehensive 2023 incidence and prevalence statistics with a focus on the H1N1 burden by top regions. Our analysis includes regional vaccination coverage levels, giving readers an easy understanding of immunization programs. We investigate doses delivered and observe long-term distribution patterns. In addition, we evaluate government and private vaccination programs, exposing strategic investments in immunization efforts. Finally, our report provides supply and distribution patterns and reviews production capacity and global vaccine availability, providing a balanced market view.
Drivers
Rising prevalence of influenza and pandemic threats accelerating the market growth.
The growing incidence of influenza outbreaks, such as H1N1 (swine flu), continues to fuel the need for vaccination. Seasonal influenza, as reported by the World Health Organization (WHO), causes about 3–5 million cases of severe illness worldwide each year, with pandemics such as H1N1 in 2009 further emphasizing the importance of effective vaccines. Governments and healthcare agencies are actively encouraging vaccination campaigns to avoid future outbreaks. Recent advances include the WHO's advocacy for new influenza vaccines that cover emerging viral strains, providing greater protection. Also, developments in vaccine manufacturing, including cell-based and recombinant technologies, have enhanced the speed and capacity of vaccine production. The constant emergence of new influenza strains also underscores the need for periodic immunization, hence the demand for H1N1 vaccines.
Advancements in vaccine development and distribution are propelling the market to grow.
Advances in vaccine technology have largely driven the development of the H1N1 vaccination market. The transition towards cell-based and mRNA vaccines, such as Moderna's mRNA-1010 influenza vaccine, is transforming immunization. The next-generation vaccines have better efficacy, faster production, and increased ability to accommodate changing influenza strains. Intranasal and needle-free vaccine products, like AstraZeneca's FluMist, are also offering ease of administration, thus improving patient compliance. In addition, large pharmaceutical firms are consolidating their supply chain and distribution networks, making vaccines accessible globally. For example, Seqirus increased production of its Flucelvax to address increasing demand in several regions. The enhanced R&D investment, coupled with global cooperation for pandemic preparedness, continues to drive market growth, providing wider and more effective vaccine coverage for H1N1 and other flu strains.
Restraint
Vaccine uncertainty and misinformation are restraining the market.
One of the key constraints in the H1N1 (swine flu) vaccine market is vaccine hesitancy, fueled by misinformation and lack of trust in vaccines. Despite robust scientific evidence for the safety and effectiveness of influenza vaccines, a large segment of the population is still hesitant to be vaccinated because of fears regarding side effects, effectiveness, and conspiracy theories. Vaccine hesitation is among the WHO's global health threats number one, they say. Dissemination of misinformation on social media has helped fuel skepticism and reduce vaccination uptake. Some believe that the influenza vaccine is not required because of fallacies regarding natural immunity. Vaccine hesitation hampers global efforts at immunization, making herd immunity difficult to attain. Combating this problem demands more robust public education campaigns, open communication from the health authorities, and policy measures to combat misinformation effectively.
Opportunities
Expansion of Universal Influenza Vaccination Programs creating opportunity for the H1N1 (swine flu) Vaccination Market.
Governments and health authorities across the globe are increasingly promoting universal influenza vaccination programs, which pose a great opportunity for the H1N1 vaccination market. Most nations have adopted policies to add influenza vaccines, such as H1N1, to routine immunization programs, especially among high-risk groups like pregnant women, children, and the elderly. The CDC, for example, still recommends annual influenza vaccinations for almost all persons above six months of age. Furthermore, pandemic preparedness funding has increased, with the likes of Gavi, WHO, and country health ministries funding mass immunization campaigns. Growth in national immunization programs, combined with improved vaccine storage and delivery systems, provides a strong platform for producers to raise production and deliver to more populations. This transformation to preventative care and government-sponsored vaccination campaigns should increase the market considerably.
Challenges
Supply Chain Constraints and Distribution Inefficiencies challenging the market.
One of the key issues in the H1N1 vaccine market is the complexity of supply chain management and vaccine distribution. All vaccines, including H1N1 vaccines, have a relatively short shelf life and need stringent cold chain logistics to be viable. In low- and middle-income countries, poor storage facilities, poor transportation infrastructure, and delays in the supply chain affect vaccine availability. The picture is compounded during pandemics with unforeseen spikes in demand that can cause bottlenecks in production and shortages. Moreover, global imbalances in access to vaccines still exist, with some parts of the world struggling to get enough doses. The COVID-19 pandemic brought to the fore weaknesses in international vaccine supply chains, placing a premium on enhanced logistics and production capacity. To overcome these issues, investments in infrastructure, improved forecasting tools, and global cooperation to provide vaccines on time are necessary.
By Type
The inactivated vaccine segment dominated the H1N1 vaccination market with an 84.25 % market share in 2023, owing to its established safety profile, broad acceptance, and comprehensive utilization in national immunization programs. In contrast to live attenuated vaccines, inactivated vaccines consist of killed virus particles, which exclude the potential for causing infection, thus recommending themselves for immunocompromised persons, pregnant women, and geriatric populations. Regulatory bodies like the FDA, WHO, and CDC favor inactivated vaccines as the first line of immunization against the flu, adding to their demand. Moreover, major pharmaceutical corporations like Sanofi Pasteur, GlaxoSmithKline, and CSL Limited have made significant efforts to produce and distribute inactivated H1N1 vaccines. The ease of storage, transportation, and existing infrastructure for injectable vaccine delivery have also helped the segment dominate the market.
The live attenuated vaccine segment is expected to see the fastest growth during the forecast period because it can trigger a more robust and long-term immune response. In contrast to inactivated vaccines, live attenuated vaccines simulate natural infection by employing a weakened strain of the virus, which increases mucosal and cellular immunity. This vaccine is especially beneficial for pediatric immunization and mass vaccination campaigns because it is intranasally administered, which eliminates injections and enhances patient compliance. Advances in the formulation and manufacturing of vaccines in the recent past, along with mounting research on better stability and efficacy, are additionally propelling market adoption. Also, the increasing demand for needle-free vaccination technology and the increased emphasis on universal influenza vaccines will drive the live attenuated vaccine market to grow at a higher rate in the forecast years.
By Route of Administration
The injectable vaccine segment dominated the H1N1 (swine flu) vaccination market in 2023 because it is well-tested for efficacy, universally available, and highly accepted by healthcare practitioners. Intramuscular or subcutaneous intramuscular vaccines, which make up the majority of inactivated influenza vaccines, such as H1N1, are the regular selection in immunization programs for the country. Regulatory clearances from key health agencies like the FDA, WHO, and CDC have further supported the credibility of injectable vaccines as protectors against H1N1 infection. Moreover, the highly developed cold chain system and government-sponsored immunization programs have eased large-scale distribution. The position of injectable vaccines as first choices in high-risk groups like pregnant women, the elderly, and immunocompromised patients further consolidated their market leadership. The steady innovations of vaccine products by pharmaceutical firms, such as adjuvanted and high-dose injectable vaccines, also supported the leading position of the segment in 2023.
By Distribution Channel
The hospital pharmacy segment dominated the H1N1 (swine flu) vaccination market in 2023 with the extensive number of vaccine administrations in hospital settings, notably throughout outbreaks of flu and pandemic preparedness programs. Hospitals are the first points of contact for vaccinations, most notably for high-risk patients such as those with chronic disease, the immunocompromised, and pregnant women. Government-initiated vaccination programs and emergency stockpiling programs further escalated hospital pharmacies' involvement in distributing and administering H1N1 vaccines. Furthermore, hospitals possess improved storage facilities for temperature-sensitive vaccines to ensure proper handling and effectiveness. The availability of trained healthcare professionals within hospitals also enhances patient confidence in receiving vaccinations. Moreover, numerous nations employed hospital-based mass immunization programs to curb H1N1 outbreaks, further bolstering the segment's dominance in 2023.
North America dominated the H1N1 vaccination market with around 35.10% market share in 2023 because of its established healthcare infrastructure, robust government immunization programs, and high levels of awareness about preventing influenza. The United States and Canada have widespread vaccination coverage, with organizations such as the CDC and Health Canada actively encouraging annual influenza immunization, including H1N1 strains. Also supporting regional supply and distribution is the presence of prominent vaccine producers Sanofi Pasteur, GlaxoSmithKline, and Seqirus. The region further has extensive government investment in pandemic preparedness through initiatives such as the Biomedical Advanced Research and Development Authority (BARDA), which supports the development and stockpiling of vaccines. High vaccination rates of seasonal influenza and aggressive public health policy mean North America remains dominant in the market.
Asia Pacific is experiencing the fastest growth in the H1N1 vaccination market with 7.41% CAGR throughout the forecast period, fueled by growing government campaigns, healthcare awareness, and an enormous target base. China, India, and Japan have widened their immunization programs considerably, incorporating influenza vaccines into national policy. The escalating incidence of influenza outbreaks in the region, in addition to urbanization and climate change, has increased the need for vaccines. Moreover, indigenous vaccine producers such as Serum Institute of India and Sinovac Biotech are ramping up production to make vaccines affordable and accessible. The region is also reaping benefits from higher investments in healthcare infrastructure and global partnerships for vaccine delivery. With a better regulatory environment and increasing vaccination coverage, Asia Pacific is likely to continue its robust growth trend in the years ahead.
Sanofi Pasteur (Fluzone, Influenza A (H1N1) 2009 Monovalent Vaccine)
GlaxoSmithKline (GSK) (Pandemrix, Fluarix)
CSL Limited (Afluria, Influenza A (H1N1) 2009 Monovalent Vaccine)
Novartis Vaccines and Diagnostics (Focetria, Fluvirin)
MedImmune LLC (FluMist, Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal)
Baxter International Inc. (Celvapan, Preflucel)
Sinovac Biotech Ltd. (PANFLU.1, Anflu)
Hualan Biological Engineering Inc. (Hualan H1N1 Influenza Vaccine, Hualan Seasonal Influenza Vaccine)
Serum Institute of India Pvt. Ltd. (Nasovac, Influvac)
Zydus Cadila (VaxiFlu-S, VaxiFlu-4)
Bharat Biotech (HNVAC, BioVac-A)
Crucell N.V. (Inflexal V, FluCell)
Daiichi Sankyo Company, Limited (Kitasato Daiichi Sankyo Flu Vaccine, BE Flu)
Mitsubishi Tanabe Pharma Corporation (Influenza HA Vaccine, Influenza HA Vaccine "KMB")
Abbott Laboratories (Influvac, Prohibit)
Pfizer Inc. (Prevenar 13, Trumenba)
AstraZeneca (Fluenz, Vaxigrip)
Johnson & Johnson (Janssen H1N1 Vaccine, Ad26.ZEBOV)
Moderna, Inc. (mRNA-1010, mRNA-1273)
Seqirus (Flucelvax, Fluad)
Suppliers (These suppliers provide essential raw materials, bioprocessing solutions, contract manufacturing, and analytical testing services for the development and production of H1N1 and other influenza vaccines.) in H1N1 (swine flu) Vaccination Market.
Thermo Fisher Scientific
Merck KGaA
Lonza Group AG
Charles River Laboratories
Cytiva (Danaher Corporation)
Sartorius AG
FUJIFILM Diosynth Biotechnologies
Wuxi Biologics
AGC Biologics
Samsung Biologics
August 2023 – The Influenza A (H1N1) 2009 Monovalent vaccines have been approved by the U.S. FDA as a strain swap to current seasonal influenza vaccines. Due to extensive experience with manufacturing and developing seasonal influenza vaccines, these vaccines take a well-recognized history of safety and success in the United States. Those H1N1 vaccines approved will be subjected to the normal testing and lot release process, like seasonal influenza vaccines, to validate their quality and effectiveness before release.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 3.54 billion |
| Market Size by 2032 | US$ 6.14 billion |
| CAGR | CAGR of 6.32% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Inactivated Vaccine, Live Attenuated Vaccine) • By Route of Administration (Injectable Vaccine, Intranasal Vaccine) • By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Sanofi Pasteur, GlaxoSmithKline (GSK), CSL Limited, Novartis Vaccines and Diagnostics, MedImmune LLC, Baxter International Inc., Sinovac Biotech Ltd., Hualan Biological Engineering Inc., Serum Institute of India Pvt. Ltd., Zydus Cadila, Bharat Biotech, Crucell N.V., Daiichi Sankyo Company, Limited, Mitsubishi Tanabe Pharma Corporation, Abbott Laboratories, Pfizer Inc., AstraZeneca, Johnson & Johnson, Moderna, Inc., Seqirus, and other players. |
Ans: The H1N1 (swine flu) Vaccination Market is expected to grow at a CAGR of 6.32% during 2024-2032.
Ans: The H1N1 (swine flu) Vaccination Market was USD 3.54 billion in 2023 and is expected to reach USD 6.14 billion by 2032.
Ans: The Rising prevalence of influenza and pandemic threats are accelerating the market growth.
Ans: The “Inactivated Vaccine” segment dominated the H1N1 (swine flu) Vaccination Market.
Ans: North America dominated the H1N1 (swine flu) Vaccination Market in 2023.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of H1N1 (2023)
5.2 Vaccination Coverage Rate (2023), by Region
5.3 Doses Administered, by Region (2020-2032)
5.4 Government and Private Vaccination Initiatives (2023)
5.5 Supply and Distribution Trends (2023-2032)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. H1N1 (swine flu) Vaccination Market Segmentation, by Type
7.1 Chapter Overview
7.2 Inactivated Vaccine
7.2.1 Inactivated Vaccine Market Trends Analysis (2020-2032)
7.2.2 Inactivated Vaccine Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Live Attenuated Vaccine
7.3.1 Live Attenuated Vaccine Market Trends Analysis (2020-2032)
7.3.2 Live Attenuated Vaccine Market Size Estimates and Forecasts to 2032 (USD Billion)
8. H1N1 (swine flu) Vaccination Market Segmentation, By Route of Administration
8.1 Chapter Overview
8.2 Injectable Vaccine
8.2.1 Injectable Vaccine Market Trends Analysis (2020-2032)
8.2.2 Injectable Vaccine Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Intranasal Vaccine
8.3.1 Intranasal Vaccine Market Trends Analysis (2020-2032)
8.3.2 Intranasal Vaccine Market Size Estimates and Forecasts to 2032 (USD Billion)
9. H1N1 (swine flu) Vaccination Market Segmentation, By Distribution Channel
9.1 Chapter Overview
9.2 Retail Pharmacy
9.2.1 Retail Pharmacy Market Trends Analysis (2020-2032)
9.2.2 Retail Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Hospital Pharmacy
9.3.1 Hospital Pharmacy Market Trends Analysis (2020-2032)
9.3.2 Hospital Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Online Pharmacy
9.4.1 Online Pharmacy Market Trends Analysis (2020-2032)
9.4.2 Online Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.4 North America H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.2.5 North America H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.6.2 USA H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.2.6.3 USA H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.7.2 Canada H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.2.7.3 Canada H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.8.2 Mexico H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.2.8.3 Mexico H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.6.2 Poland H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.6.3 Poland H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.7.2 Romania H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.7.3 Romania H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.8.2 Hungary H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.8.3 Hungary H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.9.2 Turkey H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.9.3 Turkey H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.4 Western Europe H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.5 Western Europe H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.6.2 Germany H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.6.3 Germany H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.7.2 France H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.7.3 France H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.8.2 UK H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.8.3 UK H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.9.2 Italy H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.9.3 Italy H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.10.2 Spain H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.10.3 Spain H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.13.2 Austria H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.13.3 Austria H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.4 Asia Pacific H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.5 Asia Pacific H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.6.2 China H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.6.3 China H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.7.2 India H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.7.3 India H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.8.2 Japan H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.8.3 Japan H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.9.2 South Korea H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.9.3 South Korea H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.10.2 Vietnam H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.10.3 Vietnam H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.11.2 Singapore H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.11.3 Singapore H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.12.2 Australia H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.12.3 Australia H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.4 Middle East H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.5 Middle East H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.6.2 UAE H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.6.3 UAE H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.7.2 Egypt H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.7.3 Egypt H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.9.2 Qatar H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.9.3 Qatar H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.4 Africa H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.2.5 Africa H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.6.2 South Africa H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.2.6.3 South Africa H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.4 Latin America H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.5 Latin America H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.6.2 Brazil H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.6.3 Brazil H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.7.2 Argentina H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.7.3 Argentina H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.8.2 Colombia H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.8.3 Colombia H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America H1N1 (swine flu) Vaccination Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
11. Company Profiles
11.1 Sanofi Pasteur
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 GlaxoSmithKline
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 CSL Limited
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Novartis Vaccines and Diagnostics
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 MedImmune LLC
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Baxter International Inc.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Sinovac Biotech Ltd.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Hualan Biological Engineering Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Serum Institute of India Pvt. Ltd.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Zydus Cadila
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
H1N1 (swine flu) Vaccination Market Key Segments:
By Type
Inactivated Vaccine
Live Attenuated Vaccine
By Route of Administration
Injectable Vaccine
Intranasal Vaccine
By Distribution Channel
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Atrial Fibrillation Devices Market was valued at USD 10.30 billion in 2023 and is expected to reach USD 30.47 billion by 2032, growing at a CAGR of 12.85% from 2024-2032.
The Injectable Cytotoxic Drugs Market size was USD 19.58 Billion in 2023 and is expected to Reach USD 38.15 Billion by 2032 and grow at a CAGR of 6.9% over the forecast period of 2024-2032.
Dental 3D Printing Market Size was valued at USD 3.2 billion in 2023 and is expected to reach USD 17.7 billion by 2032, growing at a CAGR of 21% over the forecast period 2024-2032.
The Ureteroscope Market Size was valued at USD 1,056.2 Million in 2023 and is expected to reach USD 1,685.14 Million by 2032 and grow at a CAGR of 5.54% over the forecast period 2024-2032.
The Artificial Teeth Market was USD 1.87 billion in 2023 and is expected to reach USD 3.83 billion by 2032, growing at a CAGR of 8.32% by 2024-2032.
The Pharma 4.0 Market was valued at 12.72 Bn in 2023 and is expected to reach 47.17 Bn by 2031, and grow at CAGR of 17.8% by forecast period 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
